Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.

"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson add...

"The market for Hepatitis C drugs is fairly large. There are high incidences of Hepatitis C in many parts of our country."

Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

During the conference, two new drugs were launched for treatment of Hepatitis C disease at affordable price.

Daclatasvir in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent i...

Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from DCGI.

Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in Ind...

Strides Arcolab today announced launch of the generic version of Hepatitis C drug 'Sofosbuvir' under the brand name 'Virso'.

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Shares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C dr...

Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Natco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.

A delegation of Gilead Sciences Inc yesterday met Commerce and Industry Minister Nirmala Sitharaman and informed about the signing of non-e...

The report said the prevalence of Hepatitis C is estimated to be within 1.8-2.5 per cent, while among drug users it is 50-90 per cent.

The IPAB revoked Roche's patent for Pegasys on grounds that the process of pegylation did not enhance the efficacy of the drug.